La vendita allo scoperto per LYTUS TECHNOLOGIES HLDGS PTV LTD SHS NEW COM 60:1 dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di LYTUS TECHNOLOGIES HLDGS PTV LTD SHS NEW COM 60:1. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

LYTUS TECHNOLOGIES HLDGS PTV LTD SHS NEW COM 60:1 (NASDAQ:LYT) Azioni, Report sulle vendite allo scoperto

Lytus Technologies Hldgs

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AGRI

ATNM

ATPC

BJDX

CHGG

CNSP

HPAI

LCID

LUMN

PLTR

RXST

SERV

SMFG

SPWR

TENK

TPET

UPXI

Pre-market: Palantir guida i rialzi con un +9,6%, mentre SunPower e Chegg mostrano cali significativi. Scopri i dettagli.

Chi sale e chi scende: i maggiori movimenti nel pre-market di oggi

LYTUS TECHNOLOGIES HLDGS PTV LTD SHS NEW COM 60:1

LYTUS TECHS HLDGS PTV LTD by Lytus Technologies Holdings PTV. Ltd.

Lytus Technologies Holdings Pvt Ltd

LSI Industries Inc

Old Republic Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORI#NYSE">ORI</a>) has outperformed the market over the past 5 years by 5.46% on an annualized basis producing an average annual return of 21.65%. Currently, Old Republic Intl has a market capitalization of $9.79 billion. 
Buying $100 In ORI: If an investor had bought $100 of ORI stock 5 years ago, it would be worth $282.80 today based on a price of $39.62 for ORI at the time of writing.
<h3>Old Republic Intl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743549315_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Old Republic Intl 5 Years Ago Would Be Worth This Much Today

Shares of big tech companies, especially the Magnificent Seven, have dropped over the past six weeks as President Donald Trump's tariff agenda drove a wave of uncertainty through the market. 
Wedbush analyst Dan Ives pointed to two major concerns for tech investors ahead of Trump's "Liberation Day" tariff <a href="https://www.benzinga.com/government/regulations/25/03/44575292/trump-to-target-dirty-15-countries-with-tariffs-which-countries-could-be-included">announcements expected Wednesday. </a>
Expert Ideas: Ives said the two biggest concerns for tech investors are a possible slowdown in AI spending amid the economic uncertainty and Beijing's potential retaliation to Trump's tariffs.&nbsp;
AI Spending Slowdown: Trump's tariff rollout threatens to inject caution into corporate spending, potentially delaying AI projects as businesses grapple with higher costs and economic uncertainty.
Read Next:<a href="https://www.benzinga.com/government/regulations/25/03/44517885/trump-slaps-25-tariffs-on-autos-what-it-means-for-your-next-car-purchase"> Trump Slaps 25% Tariffs On Autos: What It Means For Your Next Car Purchase</a>&nbsp;
"In covering tech stocks and markets the last 25 years, we have seen some &#8216;fork in the road&#8217; political moments that have created major uncertainty for the markets&#8230;.and this Trump tariff announcement is up at the top of that list," Ives wrote. 
While AI adoption and investment remain robust, the near-term growth trajectory could stall if tariffs dampen demand and squeeze margins. 
The Wedbush analyst also noted tariffs are ultimately paid for by consumers and decreased consumer confidence and spending could weigh further on companies like Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>). 
China: Beijing's response to the tariffs is another wildcard for tech stocks, especially semiconductor supply chains which are "cemented" in Asia, Ives said.&nbsp;
Retaliatory measures could disrupt production of critical components of NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips and accelerate China's push for self-reliance.  
Relocating even a fraction of Asia's semiconductor infrastructure to the U.S. would take years and cost hundreds of billions, leaving tech exposed to prolonged volatility.&nbsp;
"It would take three-four years to move even 10% of the supply chain from Asia to the U.S. in our view and cost hundreds of billions along with major supply chain delays and challenges in between," Ives warned. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/03/44575292/trump-to-target-dirty-15-countries-with-tariffs-which-countries-could-be-included">Trump To Target &#8216;Dirty 15&#8217; Countries With Tariffs: Which Countries Could Be Included?</a>&nbsp;</li>
</ul>
Photo: Shutterstock

Analyst Color

Politics

Global

Analyst Ratings

Tech

AAPL

NVDA

TSLA

Trump's 'Liberation Day' Creates 'Major Uncertainty' For Big Tech, Analyst Dan Ives Says

Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) has outperformed the market over the past 15 years by 1.05% on an annualized basis producing an average annual return of 11.98%. Currently, Lockheed Martin has a market capitalization of $105.24 billion. 
Buying $1000 In LMT: If an investor had bought $1000 of LMT stock 15 years ago, it would be worth $5,436.74 today based on a price of $448.64 for LMT at the time of writing.
<h3>Lockheed Martin's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743548419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Lockheed Martin Stock In The Last 15 Years

Back in 2019, <a href="https://www.benzinga.com/personal-finance/25/03/44461713/elon-musk-said-youll-need-to-work-at-least-80-hours-a-week-to-make-an-impact-nobody-ever-changed?utm_campaign=partner_feed&amp;utm_source=aol&amp;utm_medium=partner_feed&amp;utm_content=site">Elon Musk was surprisingly upbeat</a> for a guy juggling rockets, cars, and a brain-chip startup. At a <a href="https://www.youtube.com/live/r-vbh3t7WVI?si=TEOP6EiMVCBcA3qg">Neuralink event at the California Academy of Sciences</a>, Musk made it clear—he wasn't buying into the whole "everything's terrible" narrative.
"Humanity can address a lot of the suffering that occurs in the world and make things a lot better," he said. "I think a lot of times people are quite sort of negative about the present and about the future, but really if you are a student of history, when else would you really want to be alive?"
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/arrived-centennial">Jeff Bezos-Backed Arrived Homes Hits A Big Sale On Charlotte Property – Investors Earning A 34.7% Return</a></li>
</ul>
In Musk's eyes, now is actually the best time to be alive—yes, even with traffic, taxes, and inflation. "Those who think the past is better have not read enough history," he added.
Sure, the past had pyramids and the Renaissance, but it also had leech treatments and no Wi-Fi. Musk wasn't glamorizing a hyper-idealized future either—he was pointing out that progress is messy, but it's progress nonetheless.
Fast-forward to 2024, and Musk's optimism hasn't exactly dimmed—it just got a high-tech upgrade.
At the <a href="https://vivatechnology.com/media/press-releases/breaking-news-elon-musk-returns-to-vivatech-for-an-exclusive-q-and-a-session">VivaTech conference in Paris</a>, Musk dropped another headline-grabber: "In a benign scenario, <a href="https://www.benzinga.com/general/24/05/39044740/probably-none-of-us-will-have-a-job-elon-musk-predicts-massive-job-losses-due-to-ai">probably none of us will have a job</a>." A little jarring, yes. But according to Musk, it's not all doom and robots. He sees a future where AI and automation handle most of the work, freeing humans to pursue hobbies and passions.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
He wasn't suggesting mass layoffs or some grim, jobless wasteland. The point, he explained, is that <a href="https://finance.yahoo.com/news/dont-think-were-going-choice-233043707.html">jobs might not be necessary in the way we know them</a>. With enough technological progress, "you can have a high-quality standard of living without needing to work."&nbsp;
In true Musk fashion, <a href="https://www.benzinga.com/tech/25/03/44526637/elon-musk-says-ai-will-be-smarter-in-10-years-than-humans-who-will-have-a-much-higher-standard-of-living">he doubled down on hope</a>.
Earlier this month, during a <a href="https://x.com/i/broadcasts/1DXxyqnNoqbxM">company-wide Tesla meeting</a>, Musk thanked his team for being part of what he described as a handpicked group "destined to make history." He told employees across the globe: "What I'm here to tell you is that the future is incredibly bright and exciting, and we're going to do things that no one I think has even dreamed of."
Call it Musk's version of a halftime locker room speech—but for a team building the future. And with Tesla under scrutiny and investors wary of his side quests, the reassurance wasn't just motivational fluff. It was strategy.
See Also: <a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a>
Wedbush analyst and longtime Tesla bull Dan Ives described it as much-needed "hand holding" for investors during what he called a "dark brand crisis tornado." Translation: Musk knew things were looking shaky and did what he does best—throw big vision at big problems.
So, where does that leave us?
Somewhere between "the past wasn't that great" and "the future might not require a resume." Musk is betting on a world that doesn't just survive disruption—it thrives on it. And while he's known for outlandish timelines and bold predictions, the core message hasn't really changed since 2019: stop doomscrolling and zoom out.
Things aren't perfect, but they've never been perfect. And if you ask Musk, now's still the best time to be alive—even if the robots are coming.
Read Next:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>

Personal Finance

Elon Musk Says We're Living in the Best Time — And If You Disagree, You Probably Should Read a History Book: 'When Else Would You Want To Be Alive?'

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) CEO RJ Scaringe didn't hold back at the NVIDIA GTC conference when he shared being upset at how far ahead China is than the<a href="https://www.benzinga.com/top-stories/25/03/44313558/nvidia-stock-reached-all-time-highs-after-jensen-huangs-ces-keynote-will-next-weeks-gtc-spark-another-surge"> U.S. in EV market share. </a>
Here's what Scaringe said sets China apart and how the U.S. can catch up.
What Happened: Scaringe has positioned Rivian to be a <a href="https://www.benzinga.com/news/25/01/42986863/us-electric-vehicle-sales-hit-record-1-3-million-units-in-2024-despite-tesla-declines-top-10-bestsel">pure-play electric vehicle company</a>, to have models that all consumers will enjoy and can afford. The company just isn't there yet and according to Scaringe it couldn't come soon enough.
During his recent GTC Conference fireside, Scaringe said 45% of all new car sales in China were electric vehicles, a figure significantly ahead of the 8% of new car sales that were EVs in the U.S.
Scaringe said China is innovating in the electric vehicle space at "lightning speed," as reported by <a href="https://electrek.co/2025/03/31/rivian-ceo-why-china-leads-evs-how-the-us-can-catch-up/">Electrek</a>. The Rivian CEO said China is advancing battery technology, adding new models constantly and has vehicles priced conveniently for consumers.
The Rivian CEO compares that to the American market where technology isn't advancing as much and there are only "two great, high compelling choices" priced under $50,000.
Scaringe highlights the Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model Y and Model 3 as being examples of electric vehicles under $50,000.
While Tesla has options and is leading the way, Scaringe says other automotive companies need to do more to keep up with China, including having vehicles priced under $50,000.
Rivian currently offers the R1S SUV and R1T electric pickup truck, which are both priced over $50,000. Rivian's R2 will increase the customer base of who can afford their electric vehicles, Scaringe said.
Scaringe said the R2 offers "the magic of what is a Rivan at that higher price and puts it into a slightly smaller package." The R2 will open up the potential customer base "dramatically" with a starting price of around $45,000, Scaringe said.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44494216/rivian-doubles-down-on-ev-innovation-with-micromobility-spin-off-stock-gains">Rivian Doubles Down On EV Innovation With Micromobility Spin-Off, Stock Gains</a>
Why It's Important: Even if the R2 is successful, Scaringe said the U.S. EV market needs more options. The Rivian CEO said there needs to be another "10, 15, 20 other options" under $50,000 to help the EV market truly grow in the U.S.
Scaringe says technology is also important and the company he co-founded along with Tesla have "redefined the network architecture" with integrated technology.
"You have to have the plumbing right," Scaringe said of vertical integration.
Rivian has a joint venture with Volkswagen that will see the automotive company use its software in future electric vehicles.
Scaringe <a href="https://www.benzinga.com/trading-ideas/24/11/42217317/tesla-has-best-ev-under-50k-rivian-ceo-says-in-praise-of-rival-its-a-great-brand">highlighted the Model Y</a> last year, saying it was the best electric vehicle under $50,000 available on the market.
Rivian's focus on new models under $50,000 is among the biggest catalysts for the stock moving forward. Demand for future Rivian models will show whether price point is one of the largest determining factors in buying an electric vehicle in the U.S..
RIVN Price Action: Rivian stock closed up 6.67% to $13.28 on Tuesday versus a 52-week trading range of $8.26 to $18.86. Rivian stock is up 0.2% year-to-date in 2025 and up 19.8% over the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44426492/rivian-police-cruiser-nears-debut-for-palo-alto-police-department-could-ev-company-gain-fleet-customers">Rivian Police Cruiser Nears Debut For Palo Alto Police Department: Could EV Company Gain Fleet Customers?</a></li>
</ul>
Photo: R2, Courtesy Rivian

RIVN

Rivian CEO Says US Needs More Under $50K EVs To Catch Up To China: 'You Have To Have The Plumbing Right'

L3Harris Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) has outperformed the market over the past 20 years by 1.56% on an annualized basis producing an average annual return of 9.67%. Currently, L3Harris Technologies has a market capitalization of $39.37 billion. 
Buying $1000 In LHX: If an investor had bought $1000 of LHX stock 20 years ago, it would be worth $6,329.21 today based on a price of $209.75 for LHX at the time of writing.
<h3>L3Harris Technologies's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743547510_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In L3Harris Technologies 20 Years Ago Would Be Worth Today

Back in 2008—while the markets were melting down and Wall Street was reaching for antacids—<a href="https://www.benzinga.com/personal-finance/25/03/44527315/warren-buffett-told-students-how-he-got-rich-without-raising-a-dime-then-said-youre-already-living-better-than-john-d-rockefeller">Warren Buffett</a> wasn't browsing Zillow or test-driving Lamborghinis. He was answering questions from students at the <a href="https://www.ivey.uwo.ca/media/2809438/buffett-2008.pdf">University of Western Ontario</a> and casually dropping billionaire-level perspective like it was no big deal.
"What can I possibly do with billions and billions of dollars?" Buffett said. "I don't see the fuss in having six houses with greenskeepers; I don't see the fuss in having 20 cars in the garage."
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a></li>
</ul>
This wasn't the last time Buffett shrugged off the trappings of extreme wealth. In a <a href="https://www.cbsnews.com/news/person-to-person-warren-buffett/">2012 interview with Charlie Rose</a>, he was asked, "So no desire to have lots of, a lot of mansions around the world, a big boat—all those things that your wealth would allow you to do?" Buffett replied, "I have every possession I want. I have a lot of friends who have a lot more possessions. But in some cases, I feel the possessions possess them, rather than the other way around."
The man's worth over $164 billion and still lives in the same Omaha house he bought in 1958 for $31,500 and drives a 2014 Cadillac. While hedge fund managers chase private jets and penthouses, Buffett's idea of a splurge is a Coke and a <a href="https://www.benzinga.com/personal-finance/24/10/41230382/warren-buffett-lets-the-stock-market-decide-his-mcdonalds-breakfast-order-when-its-up-he-spends-">McDonald's breakfast sandwich</a>—preferably with exact change.
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
He reminded students that it's not about stacking assets for show, but finding a life you actually enjoy waking up to. "The problem is not getting rich, but finding a game you enjoy and living a normal life," he said.
And if you think he's all dollars and spreadsheets, he pivoted from billion-dollar valuations to marriage advice without missing a beat. "The <a href="https://www.benzinga.com/personal-finance/25/03/44182984/warren-buffett-spent-71-years-of-his-life-married-and-says-the-secret-to-a-long-lasting-marriage-is-finding-someone-with-low-expectations">most important thing is finding the right spouse</a>… If you make that one decision right I will guarantee you a good result in life."
Buffett's tone was relaxed, even playful. When asked what qualities to look for in a partner, he deadpanned: "Humor, looks, character, brains—or just someone with low expectations."
See Also: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
While Wall Street churned through chaos, Buffett sat in Omaha telling a room full of business students that a satisfying life doesn't come with a dozen garages or live-in groundskeepers. It comes from doing what you love, treating money like a tool—not a trophy—and maybe marrying someone who thinks you're hilarious.
It may have been 17 years ago, <a href="https://www.benzinga.com/personal-finance/24/11/41949050/bill-gates-warned-the-u-s-will-experience-another-2008-style-financial-crisis-he-cant-predict-when-but-says-this-is-a-certainty">but the wisdom still hits</a>. Back when Buffett made those remarks, Facebook was still shiny and new, flip phones were king, and people were updating their Top 8 on MySpace. Now it's TikTok trends and digital real estate in the metaverse—but Buffett's message hasn't aged a day. In a world obsessed with more, he's proof that enough can actually be… enough.
Read Next:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Warren Buffett Asked 'What Can I Possibly Do With Billions and Billions of Dollars?' — Sees No  Reason To Own '6 Houses or 20 Cars'

FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) has outperformed the market over the past 15 years by 1.87% on an annualized basis producing an average annual return of 12.8%. Currently, FactSet Research Systems has a market capitalization of $17.38 billion. 
Buying $100 In FDS: If an investor had bought $100 of FDS stock 15 years ago, it would be worth $612.45 today based on a price of $457.01 for FDS at the time of writing.
<h3>FactSet Research Systems's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743546619_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0401" target="_blank" rel="noreferrer noopener">&nbsp;and individual tickers.</a>
Here is a look at the most-searched stocks on Benzinga Pro for the month of March. Current prices and year-to-date performance are based on April 1 prices and do not include dividends.
1. Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
<ul>
<li>Current Price: $269.44</li>
<li>52-Week Range: $138.80 to $488.54</li>
<li>Year-to-Date Return: -28.9%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: 2nd</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44124338/exclusive-februarys-20-most-searched-tickers-on-benzinga-pro-where-do-tesla-palantir-alibaba-nvidia-rank">February Search Rank</a>: 5th</li>
</ul>
2. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)
<ul>
<li>Current Price: $556.96</li>
<li>52-Week Range: $493.86 to $613.23</li>
<li>Year-to-Date Return: -4.7%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: 3rd</li>
<li>February Search Rank: 3rd</li>
</ul>
3. NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
<ul>
<li>Current Price: $108.05</li>
<li>52-Week Range: $75.61 to $153.13</li>
<li>Year-to-Date Return: -21.9%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: 1st</li>
<li>February Search Rank: 2nd</li>
</ul>
4. Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)
<ul>
<li>Current Price: $468.31</li>
<li>52-Week Range: $413.07 to $540.90</li>
<li>Year-to-Date Return: -8.3%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: 8th</li>
<li>February Search Rank: 17th</li>
</ul>
5. MicroAlgo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>)
<ul>
<li>Current Price: $22</li>
<li>52-Week Range: $1.11 to $509.40</li>
<li>Year-to-Date Return: +517.9%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: Not in Top 20</li>
<li>February Search Rank: Not in Top 20</li>
</ul>
6. Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)
<ul>
<li>Current Price: $82.83</li>
<li>52-Week Range: $20.33 to $125.41</li>
<li>Year-to-Date Return: +10.2%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: 7th &nbsp;</li>
<li>February Search Rank: 4th</li>
</ul>
7. Visionary Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>)
<ul>
<li>Current Price: $3.19</li>
<li>52-Week Range: $1 to $9.60</li>
<li>Year-to-Date Return: +30.7%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: Not in Top 20 &nbsp;</li>
<li>February Search Rank: Not in Top 20</li>
</ul>
8. Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
<ul>
<li>Current Price: $221.45</li>
<li>52-Week Range: $164.08 to $260.09</li>
<li>Year-to-Date Return: -9.2%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: 5th &nbsp;</li>
<li>February Search Rank: 16th</li>
</ul>
9. Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>)
<ul>
<li>Current Price: $34.59</li>
<li>52-Week Range: $17.25 to $106.90</li>
<li>Year-to-Date Return: +15.1%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: 4th &nbsp;</li>
<li>February Search Rank: 1st</li>
</ul>
10. D-Wave Quantum Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>)
<ul>
<li>Current Price: $7.37</li>
<li>52-Week Range: 75 cents to $11.95</li>
<li>Year-to-Date Return: -11.67%</li>
<li><a href="https://www.benzinga.com/trading-ideas/25/01/42802731/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-2024-where-do-tesla-nvidia-gamestop-trump-media-stocks-rank" target="_blank" rel="noreferrer noopener">2024 Benzinga Pro Search Rank</a>: Not in Top 20 &nbsp;</li>
<li>February Search Rank: Not in Top 20</li>
</ul>
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent040125">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Honorable Mentions:&nbsp;The following stocks were the 11th&nbsp;to 20th&nbsp;most-searched tickers on&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent030425&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;in February.
<ul>
<li>11. Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</li>
<li>12. Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</li>
<li>13. Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</li>
<li>14. CervoMed Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>)</li>
<li>15. Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>)</li>
<li>16. MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)</li>
<li>17. Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</li>
<li>18. Aclarion Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>)</li>
<li>19. Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</li>
<li>20. Applovin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>)</li>
</ul>
Why It's Important: Tesla retook the crown in March as the most-searched ticker on Benzinga Pro, narrowly edgeing out the SPDR S&amp;P 500 ETF Trust. Tesla ranked first or second in many searches over the past two years and finished 2024 as the second most-searched ticker before falling to fifth place in February.
The Invesco QQQ Trust was one of the biggest gainers in March going from 17th place in February to fourth place in March. Apple also rejoined the top 10 going from 16th place to eighth place.
Super Mico Computer, which ranked first in the month of February, fell to ninth place in March. The company continues to be one of the most-searched tickers on Benzinga Pro in recent months.
The list of most-searched tickers in March looked significantly different, with only seven of the top 10 coming from the list of the 20 most-searched tickers in February. Of those seven tickers, five ranked in the top 10 in both February and March.
Newcomers in March included MicroAlgo, Visionary Holdings and D-Wave Quantum. Each of these stocks had major news in the month.
MicroAlgo<a href="https://www.benzinga.com/news/25/03/44463040/why-microalgo-mlgo-stock-is-skyrocketing"> announced a $20 million offering</a> in March
Visionary Holdings <a href="https://www.benzinga.com/news/25/03/44168361/visionary-holdings-gv-stock-is-up-320-this-week-whats-going-on">announced a $1 billion </a>financing deal with Qatar's Alfardan Group to help support R&amp;D and global expansion of new energy vehicles.
D-Wave <a href="https://www.benzinga.com/25/03/44333718/d-wave-quantum-stock-surges-following-strong-q4-bookings-growth-whats-going-on">reported fourth-quarter bookings</a> of $18.3 million, up 502% year-over-year.
In the 11th through 20th positions, Amazon, Intel and Applovin were the carryovers from February's top 20 most-searched tickers. The stocks ranked 13th, 18th and 14th, respectively, in the month of March.
Of the 10 stocks ranked 11th to 20th, five were among the 20 most-searched tickers in 2024 with Amazon, Intel, MicroStrategy, Meta Platforms and Microsoft all ranking in the top 20.
Among the notable stocks to miss out on the March list was Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), which ranked 11th in February and was the sixth most-searched ticker on Benzinga Pro in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43041374/exclusive-how-high-will-sp-500-go-under-donald-trump-in-2025-readers-are-optimistic-26-say-this">EXCLUSIVE: How High Will S&amp;P 500 Go Under Donald Trump In 2025? Readers Are Optimistic, 26% Say This…</a></li>
</ul>
Photo: Insta_Photos via Shutterstock

Exclusives

ACON

AMZN

AVGO

CRVO

INTC

MLGO

MSFT

MSTR

PSTV

QBTS

SMCI

EXCLUSIVE: March's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?

Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">close to 15%</a> decline in stock value year-to-date coincided with Donald Trump&#8217;s inauguration as the U.S. president on January 21.
The market remains jittery over the contract chipmaker&#8217;s potential failure to deliver in sync with the expansion of U.S. manufacturing, ultimately taking a toll on its profit margins, the Financial Times <a target="_blank" href="https://www.ft.com/content/34106b33-a6b1-4de7-ae76-e0e801534d9b" rel="noreferrer noopener">reports</a>.
Speculations included how Taiwan Semiconductor&#8217;s additional investment aimed to fix the manufacturing operations of its struggling rival Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), following which the U.S. might prompt the Taiwanese chipmaker to divest operations being a monopoly.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="392" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01080129/image-10-1024x392.png" alt="" class="wp-image-850983" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01080129/image-10-1024x392.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01080129/image-10-300x115.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01080129/image-10-768x294.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01080129/image-10-1536x587.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/01080129/image-10.png 1791w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Also Read: <a target="_blank" href="https://in.benzinga.com/25/03/44493961/nvidia-faces-17-billion-threat-in-china-as-chip-rules-tighten-and-huawei-gains-ground" rel="noreferrer noopener">In Geopolitical Chess, China&#8217;s Latest Energy Norms Block Nvidia&#8217;s Chip Strategy Amid US Sanctions</a>
TSMC has yet to elaborate on the incremental $100 billion investment, unlike its first commitment to invest in production capacity in Arizona in 2020.
It then mentioned a construction and commercial production start date and named the process technology generation. It offered similar transparency when it ramped up its investment plans to $40 billion in late 2022 and then to $65 billion in April 2024.
This time, the company only said it would build three more fabrication plants, or fabs, on top of the three previously announced ones, plus two facilities for packaging several chips together on one substrate.
On March 3, Taiwan Semiconductor chief CC Wei announced a further $100 billion investment in the U.S. in response to Trump&#8217;s alleged accusations of Taiwan &#8220;stealing&#8221; the U.S. semiconductor business.
Trump said the additional investment would bring more chip manufacturing into U.S. territory.
The additional $100 billion was an estimated price tag for plans that had been on the books for the long term. Reportedly, the company acquired enough land in 2020 to build six fabs.
Separate reports indicated Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/25/03/44563420/despite-us-expansion-taiwan-semiconductor-reaffirms-commitment-to-home-base-with-new-initiatives-reuters" rel="noreferrer noopener">reaffirming Taiwan&#8217;s commitment</a> to domestic investments and keeping the advanced tech in Taiwan.
In 2023, Taiwan Semiconductor held 67% of the market share in contracted semiconductor manufacturing and ~80% in advanced technology products.
Taiwan Semiconductor accounts for&nbsp;over a third&nbsp;of the Taiwan benchmark&#8217;s weight.
Price Action:&nbsp;TSM closed higher by 1.59% to $168.64 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/emerging-markets/25/03/44535967/tariff-fears-and-ease-in-demand-hype-slows-semiconductor-expansion" target="_blank" rel="noreferrer noopener">Tariff Fears And Ease In Demand Hype Slows Semiconductor Expansion</a></li>
</ul>
Image via Shutterstock

Media

Taiwan Semiconductor Is Down 15% Year-To-Date And Investors Are Concerned About Its Expansion Plans

The Hartford Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) has outperformed the market over the past 5 years by 13.46% on an annualized basis producing an average annual return of 29.65%. Currently, The Hartford Insurance Gr has a market capitalization of $35.50 billion. 
Buying $1000 In HIG: If an investor had bought $1000 of HIG stock 5 years ago, it would be worth $3,869.05 today based on a price of $124.39 for HIG at the time of writing.
<h3>The Hartford Insurance Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743545727_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In The Hartford Insurance Gr 5 Years Ago Would Be Worth Today

Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.5, with a high estimate of $90.00 and a low estimate of $71.00. Experiencing a 5.11% decline, the current average is now lower than the previous average price target of $81.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544928_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Trex Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Collin Verron</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$85.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Rehaut</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$73.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jeffrey Stevenson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Hold</td>
<td>$71.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$71.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Kurt Yinger</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>John Lovallo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Rafe Jadrosich</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$79.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Trex Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Trex Co compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Trex Co's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Trex Co's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TREX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Trex Co analyst ratings.</a>
<h2>About Trex Co</h2>
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
<h3>Trex Co: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Trex Co faced challenges, resulting in a decline of approximately -14.36% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Trex Co's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 5.83%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Trex Co's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.75%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.3.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TREX

Analyst Expectations For Trex Co's Future

Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $59.0, a high estimate of $65.00, and a low estimate of $57.00. A decline of 3.28% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544883_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Harrow among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$57.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Harrow. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Harrow compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Harrow's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Harrow's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HROW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Harrow analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Harrow</h2>
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
<h3>Financial Insights: Harrow</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Harrow showcased positive performance, achieving a revenue growth rate of 83.83% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Harrow's net margin excels beyond industry benchmarks, reaching 10.14%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Harrow's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.62% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Harrow's ROA stands out, surpassing industry averages. With an impressive ROA of 1.83%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 3.29, Harrow faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HROW

Where Harrow Stands With Analysts

In the last three months, 19 analysts have published ratings on Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $237.63, a high estimate of $260.00, and a low estimate of $190.00. This current average reflects an increase of 6.48% from the previous average price target of $223.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544869_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Zscaler among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Todd Weller</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$255.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$242.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$233.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$225.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$225.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zscaler. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zscaler compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Zscaler's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Zscaler's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zscaler analyst ratings.</a>
<h2>Delving into Zscaler's Background</h2>
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
<h3>Zscaler: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Zscaler showcased positive performance, achieving a revenue growth rate of 23.41% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1.19%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.51%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Zscaler's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.16%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Zscaler's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.77.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Zscaler Stands With Analysts

Ratings for Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $18.2, along with a high estimate of $21.00 and a low estimate of $14.40. This current average represents a 9.54% decrease from the previous average price target of $20.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544860_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Macerich's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Caitlin Burrows</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$14.40</td>
<td>$16.70</td>
</tr>
<tr>
<td>Michael Mueller</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Alexander Goldfarb</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Macerich. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Macerich compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Macerich's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MAC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Macerich analyst ratings.</a>
<h2>All You Need to Know About Macerich</h2>
Macerich invests in premium mall assets. The company owns 30 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.9 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in December 2024.
<h3>Macerich: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Macerich displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 14.66%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Macerich's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -77.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Macerich's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -8.03%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Macerich's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.62%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Macerich's debt-to-equity ratio is below the industry average at 1.84, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Macerich

Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) has outperformed the market over the past 10 years by 4.68% on an annualized basis producing an average annual return of 15.15%. Currently, Aon has a market capitalization of $86.14 billion. 
Buying $1000 In AON: If an investor had bought $1000 of AON stock 10 years ago, it would be worth $4,076.56 today based on a price of $398.81 for AON at the time of writing.
<h3>Aon's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743544851_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

In the preceding three months, 10 analysts have released ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Myriad Genetics and provided 12-month price targets. The average target is $17.1, accompanied by a high estimate of $29.00 and a low estimate of $11.00. Highlighting a 14.76% decrease, the current average has fallen from the previous average price target of $20.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1743544820_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Dave Weiner</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$19.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Myriad Genetics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Myriad Genetics</h2>
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
<h3>Breaking Down Myriad Genetics's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Myriad Genetics displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.12%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Myriad Genetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -20.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Myriad Genetics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -5.93%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Myriad Genetics's ROA stands out, surpassing industry averages. With an impressive ROA of -4.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 0.2, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MYGN

10 Analysts Assess Myriad Genetics: What You Need To Know

In the current session, the stock is trading at $264.54, after a 0.03% spike. Over the past month, Travelers Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) stock increased by 3.46%, and in the past year, by 15.49%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1743544819_0.png" alt="Past Year Chart" />

<h3>Evaluating Travelers Companies P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Travelers Companies has a lower P/E than the aggregate P/E of 17.76 of the Insurance industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743544819_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Price Over Earnings Overview: Travelers Companies

The Company has agreed to pay certain fees and costs associated with the review to avoid costs of litigation.
The resolution is within an accrued amount established by the Company more than two years ago. As a result, there is no current or future financial impact to the Company or its subsidiaries.

Legal

Universal Insurance Reports Conclusion Of Claim Data Review Related To Hurricane Irma, Which Occurred In September 2017; Conclusion Includes State's Full And Final Dismissal Of Former Employee's Assertions

Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) has outperformed the market over the past 5 years by 13.43% on an annualized basis producing an average annual return of 29.63%. Currently, Occidental Petroleum has a market capitalization of $46.23 billion. 
Buying $100 In OXY: If an investor had bought $100 of OXY stock 5 years ago, it would be worth $378.38 today based on a price of $49.19 for OXY at the time of writing.
<h3>Occidental Petroleum's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743543909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Occidental Petroleum Stock In The Last 5 Years

Press Releases

Lytus Technologies  enters the audio entertainment sector with the launch of Radio Room, India's first regional Audio OTT platform

Lytus Technologies  Expands Its Footprint into Healthcare with Cutting-Edge Patient-Centric HealthTech Platform

Lytus Technologies Expands HealthTech Initiatives and Strengthens Growth Trajectory

"Technology Stocks to Watch: CSDX, LYT, SINT, TRNR, RSLS, CYCU, TRUG Market Momentum Building"

UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside

Comments

LYTUS TECHNOLOGIES HLDGS PTV LTD SHS NEW COM 60:1

Vendite allo scoperto

LYTUS TECHNOLOGIES HLDGS PTV LTD SHS NEW COM 60:1 (NASDAQ:LYT) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO